Suggestions
Tom Frohlich
Biotech Executive
Tom Frohlich is a seasoned life sciences executive who recently joined the board of directors at Nested Therapeutics, a biotechnology company focused on developing precision medicine therapies for cancer.12 Here are some key details about Tom Frohlich:
Professional Experience
-
Leadership Experience: Frohlich brings over 25 years of leadership experience across multinational pharmaceutical and emerging biotech companies.1
-
Co-founder and COO: He co-founded Chinook Therapeutics in 2019 and served as its Chief Operating Officer until the company's $3.5 billion acquisition by Novartis in August 2023.2
-
Business Development: Prior to Chinook, he was Vice President of Business Development at Arbutus Biopharma, where he played a key role in multiple transactions, including the merger of Tekmira/Oncore and the spin-out of Genevant.1
-
International Experience: Frohlich has worked internationally at Johnson & Johnson and Merck, leading commercial strategy across all stages of product development, including global launches of telaprevir and STELARA® (ustekinumab).1
Education and Expertise
-
Educational Background: Frohlich holds a B.Sc. in biochemistry from the University of Victoria and an MBA from the University of Oxford.12
-
Industry Involvement: He has been associated with Versant Ventures, a healthcare investment firm, serving as an operating principal and entrepreneur-in-residence since 2018.1
Current Roles
-
Board Member: In addition to his role at Nested Therapeutics, Frohlich serves on the board of Borealis Biosciences.3
-
Life Sciences BC: He is also involved with Life Sciences British Columbia, contributing his expertise to the organization.3
Tom Frohlich's appointment to the board of Nested Therapeutics is seen as a valuable addition, bringing his extensive experience in biotech entrepreneurship, operational expertise, and commercial strategy to support the company's growth and development of innovative cancer therapies.14
Highlights
Today marks a big occasion as Novartis completes the $3.5 billion acquisition of Chinook Therapeutics. Five years ago I joined a small team at Versant Venture’s Inception Sciences site in Vancouver with the goal of creating a new biotech company. We spent about 6 months scouring the landscape and evaluating multiple opportunities before stumbling into the huge unmet need and evolving landscape of kidney disease. We quickly convinced ourselves that recent understanding of the underlying biology of renal disease and new regulatory pathways made the conditions right to discover and develop new medicines to benefit patients living with rare, severe kidney disease.
We launched Chinook at the end of 2018 and I am extremely proud of what we have accomplished in that short time. The company has grown from an idea on a power point slide to an industry leading portfolio of kidney disease assets, including two Phase 3 programs and a promising pipeline of internally discovered drug candidates. I can’t express how fulfilling it has been to build the company and to be a part of the 260+ Chinookers who have shown their dedication to the mission of developing novel therapies to make dialysis and transplant unnecessary for people living with chronic kidney disease. We’ve achieved a tremendous amount and I’m excited to see further great progress as Novartis carries forward the mission.
There are too many people from Chinook, the biotech ecosystem, and kidney disease community to recognize individually but I’m extremely grateful for the many, many hands that were involved in making Chinook an amazing and special place. As we all know, drug discovery is a team sport and Chinook wouldn’t have been the same without a truly amazing team.
I'm hiring a VP of Business Development! I'm looking for a dynamic individual to lead our business development efforts as we continue to grow the pipeline and find world-class partners to help deliver medicines to people living with kidney disease. It's an exciting role in a fast paced environment.
